I-Mab Reports Third Quarter 2024 Results

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study ofuliledlimab in first-line mNSCLC in 1H 2025

Home Previous 1 2 3 4 5 6 7 Next Tail

10 Items Per Page (Page 4 / 79) Total 781 Items

©copyright2009-2020 British Weekly      Contact Us   SiteMap